SCHEMBL3324832

SCHEMBL3324832

COc1ccccc1C1C(C(=O)OC(C)C)=C(C)NC2=C1C(=O)CC(c1ccccc1)C2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.49
KDM4E B2RXH2 8/20 0.49
HSD17B10 Q99714 7/20 0.49
HPGD P15428 5/20 0.49
CASP1 P29466 4/20 0.49
CASP7 P55210 4/20 0.49
USP2 O75604 3/20 0.49
GLA P06280 3/20 0.49
ALOX15 P16050 2/20 0.49
TP53 P04637 2/20 0.49
MAPK1 P28482 1/20 0.49
RAB9A P51151 1/20 0.49
TSHR P16473 4/20 0.48
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP2C9 P11712 1/20 0.48
GAA P10253 5/20 0.48
LMNA P02545 2/20 0.46
KMT2A Q03164 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3323418 0.90 KDM4E (0.57) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL5331923 0.89 ALDH1A1 (0.54) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL3323799 0.88 KDM4E (0.56) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL5330819 0.87 KDM4E (0.57) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL3323627 0.86 ALDH1A1 (0.55) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL3324836 0.85 ALDH1A1 (0.61) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL3329935 0.85 ALOX15 (0.53) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL3323108 0.85 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL23008940 0.85 KDM4E (0.58) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL5337234 0.83 HSD17B10 (0.64) ALDH1A1KDM4EHSD17B10HPGDCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION APP, MAPT, PSEN1 ALDH1A1 2615/4885KDM4E 4115/4885HSD17B10 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.